Table 4.
Ongoing registered clinical trials.
| Identifier | Inclusion | Arm | Sample size | Primary outcome | Status | Start date | Completion date |
|---|---|---|---|---|---|---|---|
| NCT02763761 | Immune Related Diarrhea | Arm A: Infliximab + Prednisone | N/A | Proportion of responders to less than or equal to grade 1 | Withdrawn | 16-Aug | 17-Mar |
| Arm B: Methylprednisolone + Prednisone | |||||||
| NCT04552704 | Immune related adverse events | Arm A: CD24Fc | 78 | Incidence of new adverse event; recovery rate; time to recovery from grade 2 or 3 | Active, not recruiting | 20-Oct | 22-Feb |
| Arm B: Placebo | |||||||
| NCT04375228 | Steroid-Dependent immune related adverse events | Arm A: Rituximab | 30 | Percentage of paticipants to discontinue steroid treatment | Not yet recruiting | 21-Jun | 24-Feb |
| Arm B: Tocilizumab | |||||||
| NCT04768504 | Refractory immune-related Colitis | Arm A: Tofacitinib | 10 | Clinical Remission of Diarrhea | Recruiting | 21-Nov | 23-Sep |
| NCT05195645 | Severe or corticosteroid-resistant ICI-myocarditis | Arms A-C: 10mg/kg, 20mg/kg and 25mg/kg abatacept | 21 | Proportion of CD86 receptor occupancy saturation ≥ 80% | Not yet recruiting | 22-Mar | 24-Sep |
| NCT05335928 | ICI-induced myocarditis | Arm A: Abatacept plus | 390 | Major adverse cardiac events | Not yet recruiting | 22-May | 27-Apr |
| Arm B: Placebo |
N/A, not applicable; ICI, immune checkpoint inhibitor.